Beyond CD19 CAR-T cells in lymphoma

Adoptive transfer of CD19-specific chimeric antigen receptor T-cells (CAR-T cells) has transformed the treatment paradigm of relapsed/refractory (R/R) CD19 B-cell malignancies, dramatically improving remission rates and cures in patients with chemo-refractory disease. However, the applicability of CD19 CAR-T cells is limited to B cell malignancies and antigen loss can result in treatment failure, prompting the exploration of alternative targets to overcome tumor escape via CD19 antigen loss, as well as extend the CAR-T cell platform to treat Hodgkin and T cell lymphomas. This review highlights recent clinical trials testing CAR-T cell targets beyond CD19.

Automated summary

The adoptive transfer of CD19-specific CAR-T cells has significantly improved the treatment outcomes for relapsed/refractory CD19 B-cell malignancies. However, the loss of CD19 antigen limits the applicability of CAR-T cells, leading to treatment failure. This review focuses on exploring alternative targets beyond CD19 for CAR-T cell therapy.